Yes, quick notes as follows. Sorry, rushed.- $6.5m raise, EGM in...

Yes, quick notes as follows. Sorry, rushed.

- $6.5m raise, EGM in July for stakeholder approval
- End of raise will see 568m shares at $22.7m market cap
- Craig/Niall hold 36% and quote "dont get special treatment, manically obsessed with making this successful"
- Focus is category creation e.g. Whoop, Oura. CDX targeting owning Arterial Health. CDX legacy will help form the trust in this space as already have history expertise with arterial health.
- ATCOR will tail off with Conneqt being the priority going forward. Headwinds in trial space but expect one soon.
- Conneqt, target is clinical, research and sales. Not targeting direct to consumer or patient yet. US market is their major focus as thats the biggest pond. Hence no Aus advertising.
- Not positioning to be a device company, rather be the go to for front end treatment and prevention. Lot of talk about all this. Words like mineshare, targeting biggest health disorder etc.
- signup to newsletter, provides better insight as to what they are doing day to day.
- marketing and advertising, lots learnt from the data, sounds like a continual learning and development cycle. Data to date shows Pulse is quite versatile in terms of customer base i.e. cardio health, hypertension, pregnancy, erectile dysfunction etc. Have some early insight on pricing model and reacting accordingly.
- want the conneqt app to drive engagement and personalisation, not just be a screen with numbers, rather a daily habit to maintain cardiovascular. Establish "biomarker as a service"
- CDX holds the IP and datapoints no one else can. Has real scalability. Licensing of Sohymgmorcor cloud to others in future i.e. wearables e.g. take a sognal from a Oura ring, run through cloud, then ping back.